Clinical trials: Drug Users
Healthy Volunteers
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
The main aim is to evaluate the relative abuse potential of soticlestat in healthy adults who has used central nervous system (CNS) depressants for recreational nontherapeutic reasons.
- Trial name
- NCT05602818
- Testing
- Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Takeda
Epilepsy
Risk of Urinary Retention With Retigabine
A prospective cohort study of antiepileptic drug (AED) polytherapy-treated epilepsy patients within the HealthCore Integrated Research Database (HIRD) will be conducted.
- Trial name
- NCT01462656
- Testing
- Non-EZG containing AED polytherapy, EZG containing AED polytherapy, Non-EZG AED monotherapy
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like…
- Trial name
- NCT03286218
- Testing
- Lasmiditan, Alprazolam
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Drug Abuse Illicit
Method Comparison of Intelligent Fingerprinting Drug Screening System
Prospective, multi-site, open-label, single- or double-dose, randomized, multi-site performance evaluation of accuracy of the Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and…
- Trial name
- NCT07650136
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Intelligent Bio Solutions Inc.
Abuse Potential Study
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem
- Trial name
- NCT01987739
- Testing
- 200 mg almorexant, 400 mg almorexant, 1000 mg almorexant
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Midnight Pharma, LLC
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an…
- Trial name
- NCT01272258
- Testing
- PRO 140
- Where
- United States
- Sponsor
- CytoDyn, Inc.
Pulmonary Arterial Hypertension
A Registry for Patients Taking Uptravi
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi.
- Trial name
- SPHERE (NCT03278002)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 800 people
- Sponsor
- Actelion
Postoperative Bariatric Surgery
Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Phase IV, open-label, multicenter, non-randomized, with 2 non-comparative investigational arms study, carried out in morbid obesity patients who had undergone gastric bypass surgery for body weight reduction
- Trial name
- NCT00608712
- Testing
- Esomeprazole
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Narcotic Abuse, Opioid-related Disorders
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine sulfate CR tablets and placebo in healthy male…
- Conditions
- Narcotic Abuse, Opioid-related Disorders, Analgesia, Chronic Pain
- Trial name
- NCT01595867
- Testing
- EMBEDA - morphine sulfate/ naltrexone hydrochloride, morphine sulfate CR crushed.
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid Overdose
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and…
- Trial name
- NCT05219669
- Testing
- Nalmefene Hydrochloride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Opiant Pharmaceuticals Inc
Healthy Volunteer
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users.
- Trial name
- NCT01438749
- Testing
- RO4917838, diazepam
- Where
- United States
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Recreational Drug Use
A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)
This will be a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential, safety and pharmacokinetics of orally administered PF614 relative to oxycodone IR (immediate-release)…
- Trial name
- NCT05571345
- Testing
- PF614, Oxycodone Hydrochloride 40 mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ensysce Biosciences
HIV Infections, HIV Seronegativity
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Trial name
- NCT00006327
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1
- Where
- Thailand
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- VaxGen
Opioid-induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced…
- Trial name
- NCT03720613
- Testing
- Naldemedine, Lubiprostone, Naloxegol
- Where
- United States
- Volunteers
- 34,532 people
- Sponsor
- BioDelivery Sciences International
Pain, Acute Pain
A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused
The purpose of this clinical study was to evaluate whether healthy adults, who sometimes take drugs for pleasure, are likely to abuse GRT0151Y. This abuse potential is assessed at three different doses of GRT0151Y.
- Trial name
- NCT03768024
- Testing
- GRT0151Y 50 mg capsule, Hydromorphone IR 4 mg
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Pain
Oxycodone User Registry (OUR)
The purpose of this study is to describe clinical and demographic characteristics of patients receiving prescription medications containing oxycodone immediate release (OXYRX), to characterize patient and prescriber perceptions…
- Trial name
- NCT00978328
- Testing
- oxycodone immediate release (OXYRX)
- Volunteers
- 827 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Substance Use Disorder, Drug Dependence,
Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User
Substance Use Disorder has been showing a rising trend all over the world including India. The project tested whether a Integrated community wide effort of Prevention and Awareness Groups (PAG) to manage substance use would have…
- Conditions
- Substance Use Disorder, Drug Dependence,, Alcohol Dependence
- Trial name
- NCT02173041
- Testing
- Prevention Awareness Groups (PAG), Standard Care
- Where
- India
- Volunteers
- 152 people
- Sponsor
- Macmillan Research Group UK